Bristol Myers Squibb to present Phase 2 pumitamig lung cancer data at ESMO 2026
BMY•Bristol Myers Squibb will present late-breaking global Phase 2 findings on pumitamig for metastatic lung cancer at ESMO 2026 in Madrid, October 23-27.
1. ESMO presentations
Bristol Myers Squibb will present cancer trial data at ESMO 2026 in Madrid, October 23-27. The presentations will include late-breaking global Phase 2 findings evaluating pumitamig for metastatic lung cancer; the drug is jointly developed with BioNTech.
2. Other trial results
The company will also present two late-breaking Phase 3 iza-bren studies, sponsored by Biokin, covering previously treated breast cancer and EGFR-mutant lung cancer. Final overall survival results from CheckMate 8HW will compare Opdivo with Yervoy against Opdivo alone or chemotherapy in metastatic colorectal cancer.
